论文部分内容阅读
目的:对黛力新联合埃索美拉唑、莫沙必利在慢性胃炎治疗中的应用效果进行分析。方法:选取我院2016年1月至2017年1月间收治的慢性胃炎患者112例作为研究对象,随机分为研究组56例及对照组56例,对照组采取埃索美拉唑、莫沙必利治疗,研究组采取黛力新联合埃索美拉唑、莫沙必利治疗,对比两组患者治疗情况。结果:研究组总有效率为96.43%,对照组总有效率为85.71%,研究组总有效率要高于对照组(P<0.05);治疗后,研究组HAD评分为(6.57±2.14)分,对照组HAD评分为(9.86±2.78)分,研究组HAD评分要低于对照组(P<0.05)。结论:黛力新联合埃索美拉唑、莫沙必利在慢性胃炎治疗效果较优,可有效控制患者相关症状,值得临床应用。
Objective: To analyze the effect of Deanxit in combination with esomeprazole and mosapride on the treatment of chronic gastritis. Methods: A total of 112 patients with chronic gastritis who were admitted to our hospital from January 2016 to January 2017 were randomly divided into study group (56 cases) and control group (56 cases). In the control group, esomeprazole, Weili treatment, the study group to take Deanxide combined with esomeprazole, mosapride treatment, compared two groups of patients treatment. Results: The total effective rate was 96.43% in the study group and 85.71% in the control group, and the total effective rate in the study group was higher than that in the control group (P <0.05). After treatment, the HAD score in the study group was (6.57 ± 2.14) , HAD score of the control group was (9.86 ± 2.78) points, HAD score of the study group was lower than that of the control group (P <0.05). Conclusion: Deanxit and esomeprazole, mosapride in the treatment of chronic gastritis better effect, which can effectively control the patient-related symptoms, it is worth clinical application.